You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

233 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
New Drug Funding Program
    Nelarabine - Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
May 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
Apr 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2024
Drug
Other Name(s): Calquence®
Jul 2024
Regimen
Intent: Palliative
Jul 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria
Jul 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    prednisone
Aug 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    dexamethasone
Aug 2024

Pages